Lysis of fibrin was first recognized by MORGAGNI in 1769, observing a liquid blood in a patient of acute death, and the phenomenon was named as fibrinolysis by DASTRE in 1893. In 1937, MACFARLANE recognized in a patient after cholecystectomy that the blood clot was lysed completely in the following morning. Since then, much attention has been paid clinically on fibrinolysis and it has been said...

The effect of recombinant factor VIIa (rFVIIa) on blood loss was evaluated in cirrhotic patients undergoing orthotopic liver transplantation. In the present study, we explored the effect of rFVIIa on coagulation and fibrinolysis during orthotopic liver transplantation. Coagulation factors, parameters of thrombin generation and parameters of fibrinolysis were measured in six patients who had rec...

Disseminated intravascular coagulation is a frequent complication of sepsis. Coagulation activation, inhibition of fibrinolysis, and consumption of coagulation inhibitors lead to a procoagulant state resulting in inadequate fibrin removal and fibrin deposition in the microvasculature. As a consequence, microvascular thrombosis contributes to promotion of organ dysfunction. Recently, three rando...

Fibrinolysis is a basic defence mechanism of the organism designed to control the deposition of fibrin in the vascular system and elsewhere. When thrombin is generated by the coagulation system it acts on fibrinogen and 'precipitates' it out of solution as a polymer-fibrin. This polymer deposition is regulated by the fibrinolytic system which acts on the insoluble protein fibrin and, by splitti...

Thrombin activatable fibrinolysis inhibitor (TAFI) is a carboxypeptidase B-like proenzyme that after activation down-regulates fibrinolysis. Platelets are known to contain antifibrinolytic factors that are secreted during platelet activation. Therefore, the presence of TAFI in platelets was analyzed. TAFI was identified in platelets in a concentration of about 50 ng/1 x 109 platelets and was se...

Background—Factor V (fV) predisposes to thrombosis by enhancing thrombin formation. This study tested the hypothesis that fV inhibits fibrinolysis in vivo. Methods and Results—Radiolabeled clots were injected into the jugular veins of wild-type mice and mice heterozygous (fV ) or homozygous (fV) for fV. Mean percent clot lysis 5 hours later was significantly reduced in fV mice (14.3 3.6%, n 13)...

The in vitro and in vivo haematological effects of puffadder (Bitis arietans) venom in the baboon (Papio ursinus) with regard to its effect on coagulation, fibrinolysis and platelet aggregation were studied. There is a delay in the intrinsic coagulation mechanism with fibrinolysis and in vitro fibrinogenolysis. Normal human platelets demonstrated an extreme susceptibility to puff-adder venom in...

Vascular disease accounts for more than 50% of deaths and in most cases the cause lies in obstruction to blood flow by the twin perils of atheroma formation and thrombosis. The major constituents of thrombi are platelets and fibrin, together with trapped red cells and other elements. Our main antithrombotic drugs are the antiplatelet agents to prevent platelets sticking together; anticoagulants...

In order to study the fibrinolytic activity of vein walls in smokers and nonsmokers, 71 randomly selected heavy smokers, i.e., smoking more than 15 g tobacco per day, and 41 nonsmokers from the population group "Men born in 1914 residing in Malmo" were invited to undergo a health examination. When examined after 12 hours' abstention from tobacco, the smokers were found to have the same fibrinol...